Subcommittee on Neurological Disease committee  The MS Society heard from our clients in November when Dr. Zamboni's work was on the public stage. We expedited a process for a research grant, which we normally don't do at the MS Society, because we heard the need for CCSVI and MS research. At that stage, we crafted a request f

Subcommittee on Neurological Disease committee  I'll start first. So what we do understand in the scientific world is that you do need to provide further evidence. So right now, Dr. Zamboni's group has provided evidence in terms of CCSVI in MS; however, it's a very small group of people, so it's a pilot study, as Dr. Zamboni

Subcommittee on Neurological Disease committee  Thank you. We understand that there's an urgency today from our clients who are wanting the treatment right now and to be tested. At the MS Society, we want to be responsible, to ensure that this treatment is safe and effective. In order to do this, we need to ensure that there

Subcommittee on Neurological Disease committee  Thank you, Madam Chair and subcommittee members. Thank you for the opportunity to speak today about CCSVI and its relationship to MS. I am speaking as a representative of the MS Society of Canada with previous experience as a basic researcher, with a focus in multiple sclerosis.